These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26414816)

  • 1. Neoadjuvant Long-Course Chemoradiotherapy for Rectal Cancer: Does Time to Surgery Matter?
    Panagiotopoulou IG; Parashar D; Qasem E; Mezher-Sikafi R; Parmar J; Wells AD; Bajwa FM; Menon M; Jephcott CR
    Int Surg; 2015 Jun; 100(6):968-73. PubMed ID: 26414816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of pathological complete response rates after neoadjuvant short-course radiotherapy or chemoradiation followed by delayed surgery in locally advanced rectal cancer.
    Hoendervangers S; Couwenberg AM; Intven MPW; van Grevenstein WMU; Verkooijen HM
    Eur J Surg Oncol; 2018 Jul; 44(7):1013-1017. PubMed ID: 29650419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing pathological complete response rate using oral capecitabine versus infusional 5-fluorouracil with preoperative radiotherapy in rectal cancer treatment.
    Jootun N; Evans T; Mak J; Makin G; Platell C
    ANZ J Surg; 2018 Jan; 88(1-2):62-65. PubMed ID: 28982208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome.
    Wolthuis AM; Penninckx F; Haustermans K; De Hertogh G; Fieuws S; Van Cutsem E; D'Hoore A
    Ann Surg Oncol; 2012 Sep; 19(9):2833-41. PubMed ID: 22451236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
    Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
    Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.
    Beddy D; Hyland JM; Winter DC; Lim C; White A; Moriarty M; Armstrong J; Fennelly D; Gibbons D; Sheahan K
    Ann Surg Oncol; 2008 Dec; 15(12):3471-7. PubMed ID: 18846402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer.
    Sloothaak DA; Geijsen DE; van Leersum NJ; Punt CJ; Buskens CJ; Bemelman WA; Tanis PJ;
    Br J Surg; 2013 Jun; 100(7):933-9. PubMed ID: 23536485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal Timing to Surgery after Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.
    Sun Z; Adam MA; Kim J; Shenoi M; Migaly J; Mantyh CR
    J Am Coll Surg; 2016 Apr; 222(4):367-74. PubMed ID: 26897480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemoradiotherapy with capecitabine followed by laparoscopic resection in locally advanced tumors of middle and low rectum - toxicity and complications of the treatment.
    Soumarova R; Skrovina M; Bartos J; Gruna J; Wendrinski A; Czudek S; Kycina R; Parvez J
    Eur J Surg Oncol; 2010 Mar; 36(3):251-6. PubMed ID: 19879716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
    Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
    J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer.
    Abdul-Jalil KI; Sheehan KM; Kehoe J; Cummins R; O'Grady A; McNamara DA; Deasy J; Breathnach O; Grogan L; O'Neill BD; Faul C; Parker I; Kay EW; Hennessy BT; Gillen P
    Colorectal Dis; 2014 Jan; 16(1):O16-25. PubMed ID: 24119076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer with serum biomarkers.
    Clarke TL; White DA; Osborne ME; Shaw AM; Smart NJ; Daniels IR
    Ann R Coll Surg Engl; 2017 May; 99(5):373-377. PubMed ID: 28462648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncological outcomes in extended time intervals betweenpreoperative chemoradiotherapy with capecitabine and surgery inoperable rectal adenocarcinoma.
    Muñoz MA; Palacios MG; Malca J; Mantilla R; Montenegro PC; Chavez I
    Rev Gastroenterol Peru; 2018; 38(1):9-21. PubMed ID: 29791416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biopsy specimens obtained 7 days after starting chemoradiotherapy (CRT) provide reliable predictors of response to CRT for rectal cancer.
    Suzuki T; Sadahiro S; Tanaka A; Okada K; Kamata H; Kamijo A; Murayama C; Akiba T; Kawada S
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1232-8. PubMed ID: 23158058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer.
    Kim DY; Jung KH; Kim TH; Kim DW; Chang HJ; Jeong JY; Kim YH; Son SH; Yun T; Hong CW; Sohn DK; Lim SB; Choi HS; Jeong SY; Park JG
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):378-84. PubMed ID: 17097835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers.
    Lim SB; Choi HS; Jeong SY; Kim DY; Jung KH; Hong YS; Chang HJ; Park JG
    Ann Surg; 2008 Aug; 248(2):243-51. PubMed ID: 18650634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative short-course concurrent chemoradiation therapy followed by delayed surgery for locally advanced rectal cancer: a phase 2 multicenter study (KROG 10-01).
    Yeo SG; Oh JH; Kim DY; Baek JY; Kim SY; Park JW; Kim MJ; Chang HJ; Kim TH; Lee JH; Jang HS; Kim JG; Lee MA; Nam TK
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):34-9. PubMed ID: 23265569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Predictive factors associated with pathologic complete response after neoadjuvant chemoradiotherapy in rectal cancer].
    Sun Y; Chi P; Xu B; Lin H; Lu X; Huang Y; Xu Z; Huang S; Jiang C
    Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Jun; 17(6):556-60. PubMed ID: 24953361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic Complete Response in Rectal Cancer: Can We Detect It? Lessons Learned From a Proposed Randomized Trial of Watch-and-Wait Treatment of Rectal Cancer.
    Nahas SC; Rizkallah Nahas CS; Sparapan Marques CF; Ribeiro U; Cotti GC; Imperiale AR; Capareli FC; Chih Chen AT; Hoff PM; Cecconello I
    Dis Colon Rectum; 2016 Apr; 59(4):255-63. PubMed ID: 26953983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preoperative chemoradiotherapy with S-1 for advanced low rectal cancer].
    Kitani K; Okajima K; Sato K; Isono S; Kimura H; Ikeda M; Inoue K; Iwama M; Tsujie M; Nakayama T; Fujiwara Y; Murata M; Yukawa M; Ota Y; Inoue M
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2122-4. PubMed ID: 22202303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.